Stories
Slash Boxes
Comments

SoylentNews is people

Submission Preview

Link to Story

Purdue Pharma Pleads Guilty to Opioid Crisis Charges, Will Become a Public Benefit Corporation

Accepted submission by takyon at 2020-10-22 01:44:45
Business

OxyContin maker to plead guilty to federal criminal charges, pay $8 billion, and will close the company [cnn.com]

Purdue Pharma, the maker of OxyContin, has agreed to plead guilty to three federal criminal charges for its role in creating the nation's opioid crisis and will pay more than $8 billion and close down the company.

The money will go to opioid treatment and abatement programs [cnn.com]. The privately held company has agreed to pay a $3.5 billion fine as well as forfeit an additional $2 billion in past profits, in addition to the $2.8 billion it agreed to pay in civil liability.
"Purdue Pharma actively thwarted the United States' efforts to ensure compliance and prevent diversion," said Drug Enforcement Administration Assistant Administrator Tim McDermott. "The devastating ripple effect of Purdue's actions left lives lost and others addicted."

The company doesn't have $8 billion in cash available to pay the fines. So Purdue will be dissolved as part of the settlement, and its assets will be used to create a new "public benefit company" controlled by a trust or similar entity designed for the benefit of the American public. The Justice Department said it will function entirely in the public interest rather than to maximize profits. Its future earnings will go to paying the fines and penalties, which in turn will be used to combat the opioid crisis.

That new company will continue to produce painkillers such as OxyContin, as well as drugs to deal with opioid overdose. Deputy Attorney General Jeffrey Rosen, who announced the settlement, defended the plans for the new company to continue to sell that drug, saying there are legitimate uses for painkillers such as OxyContin.

Also at The New York Times [archive.org], Bloomberg [bloomberg.com], NBC [nbcnews.com], and CBS [cbsnews.com].

Previously:


Original Submission